Home » PUBLICATIONS

PUBLICATIONS

PUBLICATIONS

LAVORI IN EXTENSO

Tonato M., Roila F., Del Favero A., Tognoni G., Franzosi M.G., Pampallona S. for the Italian Clinical Research Oncology Group (GOIRC):

A pilot study of high dose domperidone as antiemetic in patients treated with cisplatin.

European Journal of Cancer 21, 807-810, 1985. (IF=4.121) 
 

Roila F., Tonato M., Basurto C., Ballatori E., Del Favero A., Tognoni G., Franzosi M.G., Passalacqua R. for the Italian Clinical Research Oncology Group (GOIRC):

Antiemetic activity of two different high doses of metoclopramide (MTC) in cisplatin treated cancer patients. A randomized double blind trial.

Cancer Treatment Reports. 69, 1353-1357, 1985. (IF=5.295) 
 

Cocconi G., Tonato M., Di Costanzo F., Bisagni G., Belsanti V., Buzzi F., Ceci G.:

Platinum and Etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (GOIRC).

European Journal of Cancer and Clinical Oncology 22:761-764, 1986. (IF=4.121) 
 

De Lisi V., Cocconi G., Tonato M., Di Costanzo F., Leonardi F., Soldani M.:

Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin and mitomycin (BAFMI) in the treatment of advanced gastric cancer. A phase III trial of the Italian Oncology Group for Clinical Research (GOIRC).

Cancer Treatment Reports 70:481-485, 1986. (IF=5.295) 
 

Roila F., Tonato M., Basurto C, Bella M., Passalacqua R., MorsiaD., Di Costanzo F., Donati D., Ballatori A., Tognoni G., A. Del Favero:

Antiemetic activity of high doses of metoclopramide combined with metylprednisolone alone in cisplatin treated cancer patients: a randomized double blind trial the Italian Oncology Group for Clinical Research (GOIRC).

Journal of  Clinical Oncology. 5: 141-149, 1987  (IF=17.793) 
 

Bacchi M.:

La conduzione di uno studio multicentrico: esperienza GOIRC

in “Sillabo XII Corso di Aggiornamento in Oncologia Medica” a cura dell'AIOM, Gestioni Grafiche Stocchiero Ed., Vicenza; pp 109-128, 1988  
 

De Lisi V., Cocconi G., Tonato M., Di Costanzo F., Leonardi F., Soldani M.:

5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study the Italian Oncology Group for Clinical Research (GOIRC).

Recent Results in Cancer Research, 110:212-218, 1988. 
 

Passalacqua R., Bisagni G., Bertusi M., Donati D., Buzzi F., Di Costanzo F., Basurto C., Gori S.:

Lonidamine in advanced colorectal cancer: a phase II trial of the Italian Oncology Group for Clinical Research (GOIRC).

Tumori 75:277-279, 1989 (IF=0.863) 
 

Roila F., Tonato M., Basurto C., Picciafuoco M., Bracarda S., Donati D., Malacarne P., Monici L., Di Costanzo F., Patoia L., Ballatori E., Tognani G., Del Favero A.:

Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine. A study of the Italian Oncology Group for Clinical Research.

Journal of Clinical Oncology 7:1693-1700, 1989. (IF=17.793) 
 

Di Costanzo F., Bartolucci R., Sofra M., Calabresi F., Malacarne P., Belsanti V., Boni C., Bacchi M.:

5-fluorouracile vs alte dosi di acido folico e 5-fluorouracile nel carcinoma del colon-retto avanzato. Studio randomizzato del Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

Atti “Nuove prospettive in Oncologia - L'associazione Fluorouracile e Folati”, a cura di F. Di Costanzo, Arti Grafiche Nobili Ed. Terni, pp: 71-80, 1990 
 

Cocconi G., Di Costanzo F., Bisagni G., Bacchi M., Buzzi F., Canaletti R., Carpi A., Ceci G., Colozza A., De Lisi V., Lottici R., Passalacqua R., Peracchia G.:

Confronto fra la continuazione della chemioterapia di induzione ed una intensificazione tardiva seguita dalla sospensione di ogni chemioterapia nel carcinoma mammario metastatizzato. Studio randomizzato del Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

Proc. “Advances in management of malignancies - 2nd International Congress promoted by Fondazione Internazionale Menarini” a cura di A. Carpi, A. Sagripanti, B. Grassi, Monduzzi Ed. Bologna, pp: 407-419, 1990 
 

Cocconi G., Bisagni G., Bacchi M., Buzzi F., Canaletti R., Carpi A., Ceci G., Colozza A., De Lisi V., Lottici R., Passalacqua R., Peracchia G.

A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (GOIRC).

Annals of Oncology 1: 36-44, 1990 (IF=5.647) 
 

Cocconi G., Lottici R., Bisagni G., Bacchi M., Tonato M., Passalacqua R., Boni C., Belsanti V., Bassi P.

Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.

Cancer Investigation, 8: 327-334, 1990 
 

Cocconi G., Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, Colozza MA, De Lisi V, Lottici R, Mosconi AM, Passalacqua R, Tonato M.

Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized study the Italian Oncology Group for Clinical Research.

Journal of Clinical Oncology, 9:664-669, 1991 (IF=17.793) 
 

Di Costanzo F., Malacarne P., Zironi S., Marzola M., Corgna E., Figoli F., Bacchi M., Passalacqua R., Algeri R., Bartolucci R.

Preliminary report of high dose of folinic acid and 5-Fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.

Journal of Surgical Oncology, Suppl. 2: 137-140, 1991 
 

Cocconi G., Bisagni G., Ceci G., Bacchi M., Boni C., Brugia M., Carpi A., Di Costanzo F., Franciosi V., Gori S., Indelli M., Passalacqua R.

Low-dose aminogluthetimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research

Journal of  Clinical Oncology 10:984-989, 1992 (IF=17.793) 
 

Di Costanzo F., Bartolucci R., Calabresi F., Sofra M., Marzola M., Belsanti V., Boni C., Bacchi M.

Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC).

Annals of Oncology, 3:371-376, 1992. (IF=5.647) 
 

Cocconi G., Bella M., Calabresi F., Tonato M., Canaletti R., Boni C., Buzzi F., Ceci G., Corgna E., Costa P., Lottici R., Papadia F., Sofra M., Bacchi M.

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.

New England Journal of Medicine 327: 516-523, 1992. (IF=47.050) 
 

Di Costanzo F.

Best treatment for colorectal cancer and confirmatory trials.

Annals of Oncology 3 (3): 245-246, 1992. (IF=5.647) 
 

Bisagni G., Cocconi G., Ceci G., De Lisi V., Di Blasio B., Lottici R., Passalacqua R., Finardi C.

M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma. A phase II study.

Annals of Oncology, 5: 93-94, 1994. (IF=5.647) 
 

Cocconi G., Bella M., Zironi S., Algeri R., Di Costanzo F., De Lisi V., Luppi G., Mazzocchi B., Rodinò C., Soldani M., Gilli G., Finardi C.

Fluorouracil, Doxorubicin, and Mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research.

Journal of  Clinical Oncology 12: 2687-2693, 1994. (IF=17.793) 
 

Cocconi G, Bisagni G, Ceci G, Bacchi M:

Aminoglutethimide: the problem of the optimal dose and the indispensability or not of hydrocortisone.

In "Clinical use of aromatase inhibitors. Current data and future prospective",

G. Robustelli Della Cuna, A. Manni, F. Pannuti, EDIMES Ed., Pavia, pp. 97-105, 1994 
 

Ceci G., Bisagni G., Cocconi G., Rodinò C., Belsanti V., Bertusi M., Buzzi F., Bacchi M.:

Cisplatin and VP16 in metastatic breast carcinoma as a third line chemotherapy. A randomized study comparing low vs high doses of Cisplatin.

Tumori 81: 241-244, 1995 
 

Crinò L., Clerici M., Figoli F., Carlini P., Ceci G., Cortesi E., Carpi A., Santini A., Di Costanzo F., Boni C., Meacci M., Corgna E., Darwish S., Scarcella L., Santucci A., Ballatori E., Tonato M.

Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)

Annals of Oncology 6: 347-353, 1995. (IF=5.647) 
 

Crinò L., Clerici M., Figoli F., Barduagni M., Carlini P., Ceci G., Cortesi E., Carpi A., Santini A., Di Costanzo F. et al.

Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell ling cancer: a randomized trial by the Italian Oncology Group for Clinical Research.

Lung Cancer 12 (suppl 1): S125-132, 1995. 
 

De Lisi V., Cocconi G., Angelini F., Cavicchi F., Di Costanzo F., Gilli G., Rodinò C., Soldani M., Tonato M., Finardi C.

The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma.

Cancer 77: 245-250, 1996. 
 

Di Costanzo F., Tagliaventi M., Carlini P., Zironi S., Mazzocchi B., Bella M., Donati D., Acito L., Maggian P., Angiona S.

High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (GOIRC).

American Journal of Clinical Oncology 19 (3): 307-310, 1996. 
 

Di Costanzo F., Gasperoni S., Labianca R., Sdrobolini A., Zamparelli G., Angiona S., Bartolucci R., Rossetti R. on behalf of GOIRC and GISCAD.

Preliminary report of an ongoing trial comparing surgery alone versus surgery and chemotherapy in operable gastric cancer.

Journal of Chemotherapy 8 suppl. 4: 104-106, 1996. 
 

Passalacqua R., Cocconi G., Caminiti C., Silingardi V., Bella M.A., Bichisao E., Michiara M., Malavasi V., Donati D., Di Costanzo F., Rocca A., Di Sarra S., Scaglione F., Fraschini F.

Double-blind , multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients.

Journal of Clinical Oncology 15: 2467-2473, 1997. (IF=17.793) 
 

Di Costanzo F., Gasperoni S., Malacarne P., Belsanti V., Luppi G., Marzola M., Corgna E., Sdrobolini A., Passalacqua R., Figoli F., Algeri R., Zironi S., Angiona S., Boni C.

High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.

American Journal of Clinical Oncology 21 (4): 369-375, 1998. 
 

Boni C., Savoldi L., Bisagni G., Ceci G., Crinò L., De Lisi V., Di Costanzo F., Lasagni L., Manenti AL., Moretti G., Rondini E., Sassi M., Zadro A.

Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC).

European Journal of Cancer 34 (12): 1974-1976, 1998. (IF=4.121) 
 

Franciosi V., Cocconi G., Michiara M., Di Costanzo F., Fosser V., Tonato M., Carlini P., Boni C., Di Sarra S.

Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non small cell lung carcinoma, or malignant melanoma.

Cancer 85: 1599-1605, 1999 
 

Cocconi G., Bisagni G., Ceci G., Di Blasio B., De Lisi V., Passalacqua R., Zadro A., Boni C., Morandi P., Savoldi L.:

Three new highly active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma. A randomized phase II trial.

Breast Cancer Res. Treat.56: 125-132, 1999. IF=4.696) 
 

Cocconi G., Bella M.A., Lottici R., Leonardi F., Ceci G., Passalacqua R., Di Blasio B., Bordi C., Biscottini B., Melpignano M., De Biasi D., Finardi C., Bacchi M.:

Mature results of a prospective randomized trial comparing two different time schedule of cisplatin in advanced ovarian carcinoma.

American Journal of Clinical Oncology 22: 559-567, 1999. (IF=2.206) 
 

Cocconi G., Bisagni G., Bella M., Acito L., Anastasi P., Carpi A., Di Costanzo F., Frassoldati A., Mosconi A., Borrini A., Buzzi P.

Comparison of CMF (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer. A prospective randomized trial.

American Journal of Clinical Oncology 22: 593-600, 1999. (IF=2.206) 
 

Boni C., Bisagni G., Savoldi L., Moretti G., Rondini E., Sassi M., Zadro A., De Pas T., Franciosi V., Pazzola A., Vignoli R., Banzi M.C., Pajetta V.

Gemcitabine, Ifosfamide, Cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).

International Journal of Cancer 87: 724-727, 2000. (IF=4.722) 
 

Di Costanzo F., Canaletti R., Sdrobolini A., Olmeo N., Luppi G., Pucci F., Cavicchi F., Gasperoni S.,

Rodinò C., Zironi S., Angiona S., Contu A.

Modulation of fluorouracil by methotrexate, leucovorin and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).

American Journal of Clinical Oncology 23 (3): 314-318, 2000. (IF=2.206) 
 

Zeuli M., Pino M.S., Cognetti F.

La capecitabina nel trattamento del carcinoma colorettale.

Tumori 87 (1 suppl. 1): 55-56, 2001. (IF=0.863) 
 

Zeuli M., Di Costanzo F., Sdrobolini A., Gasperoni S., Paoloni F.P., Carpi A., Moscetti L., Cherubini R., Cognetti F. on behalf of Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC) e Gruppo Oncologico Laziale (GOL).

Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.

Annals of Oncology 12: 1737-1741, 2001 (IF=5.647) 
 

Cocconi G., Di Blasio B., Boni C., Bisagni G., Ceci G., Rondini E., Bella M., Leonardi F., Savoldi L., Camisa R., Bruzzi P.

Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.

Cancer 95: 228-235, 2002. (IF=5.418) 
 

Colozza M., Bisagni G., Mosconi A. M., Gori S., Boni C., Sabbatini R., Frassoldati A., Passalacqua R., Rosa Bian A., Rodinò C., Rondini E., Algeri R., Di Sarra S., De Angelis V., Cocconi G., Tonato M., on behalf of the Italian Oncology Group for Clinical Research (GOIRC).

Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.

European Journal of Cancer 38: 2279-2288, 2002. (IF=4.121)
 

Cocconi G., Passalacqua R., Foladore S., Carlini P., Acito L., Maiello E., Marchi M., Gebbia V., Di Sarra S., Beretta M., Bacchi M.

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study.

Melanoma Research 13: 73-79, 2003. (IF=2.061) 

 

G. Cocconi, P. Carlini, A. Gamboni, S. Gasperoni, C. Rodinò, S. Zironi, G. Bisagni, S. Porrozzi, F. Cognetti, F. Di Costanzo, R. Canaletti, E. M. Ruggeri, R. Camisa, F. Pucci.

Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.

Annals of Oncology 14: 1258-1263, 2003. (IF=5.647) 
 

G. Cocconi.

Adjuvant chemotherapy in early breast cancer: optimal and suboptimal anthracycline-containing regimens.

Breast Cancer Research and Treatment 80: 313-320, 2003. (IF=4.696) 
 

Di Costanzo F, Sobrero A, Gasperoni S, Dogliotti L, Frassineti L, Falcone A, Lionetto R, Bruzzi P, Luppi G, Gallo L, Conte P, Comandone A, Turci D, Marzola M, Folco U, Pfanner E, Mestriner M, Boni C, Galli C, Tonato M, Rosso R; Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).

Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).

Annals of Oncology 14:1365-72, 2003. (IF=5.647) 
 

RC Coombes, E Hall, LJ Gibson, M Phil, R Paridaens, J Jassem, T Delozier, SE Jones, I Alvarez, G Bertelli, O Ortmann, AS Coates, E Bajetta, D Dodwell, RE Coleman, LJ Fallowfield, E Mickiewicz, J Andersen, PE Lonning, G Cocconi, A Stewart, N Stuart, CF Snowdon, M Carpentieri, G Massimini, JM Bliss for the Intergroup Exemestane Study.

A randomized trial of Exemestane after two to three years of Tamoxifen therapy in postmenopausal women with primary brest cancer.

N Engl J Med 350: 1081-1092, 2004. (IF=47.050) 
 

Di Costanzo F, Manzione L, Gasperoni S, Bilancia D, Acito L, Angiona S, Mazzoni F, Giustini L; Italian Oncology Group for Cancer Research.

Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.

Cancer Invest. 22 (3): 331-337, 2004. (IF=2.105) 
 

Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repetto L, Merlano M, De Placido S, Torri V, Comella G, Labianca R, Parisi V, Gallo C.

Insurance for independent cancer trials.

Annals of Oncology 15 (11):1722-1723, 2004. (IF=5.647) 
 

Sobrero A, Frassineti G, Falcone A, Dogliotti L, Rosso R, Di Costanzo F, Bruzzi P; INTACC.

Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.

British Journal of Cancer 92 (1): 24-29, 2005.; errata corrige in Br J Cancer. 93: 733, 2005 (IF=4.346) 

Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P, Gasperoni S.

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian Oncology Group for Clinical Research (GOIRC).

British Journal of Cancer  93 (2): 185-189, 2005. (IF=4.346) 
 

G. Cocconi, B. Di Blasio, C. Boni, G. Bisagni, E. Rondini, M. A. Bella, F. Leonardi, L. Savoldi, C. Vallisneri, R. Camisa, P. Bruzzi, on behalf of the Italian Oncology Group for Clinical Research (GOIRC).

Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term.

Annals of Oncology 16: 1469-1476, 2005 (IF=5.647) 
 

Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clincal Research.

HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.

Clin Breast Cancer. 6(3): 253-9, 2005. (IF=2.065) 

 

Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repetto L, Merlano M, De Placido S, Torri V, Comella G, Labianca R, Parisi V, Gallo C.

Cost of insurance policies for investigator-initiated cancer clinical trials in Italy

Tumori 91 (4): 373-373, 2005 (IF=0.863) 
 

Di Costanzo F, Gasperoni S, Papaldo P, Bilancia D, Manzione L, Landucci E, Mazzoni F, Cognetti F.

Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.

Annals of Oncology 17 (1): 79-84, 2006 (IF=5.647) 
 

Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Lancet 369 (9561): 559-70, 2007; Erratum in: Lancet 369 (9565): 906, 2007. (IF=30.758) 
 

Dalla Chiesa M, Passalacqua R, Michiara M, Franciosi V, Di Costanzo F, Bisagni G, Camisa R, Buti S, Tommasello G, Cocconi G; Italian Oncology Group for Clinical Research.

Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.

Acta Biomed 78 (3): 204-209, 2007 
 

Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; On behalf of Italian Oncology Group for Cancer Research.

Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC.

J Natl Cancer Inst 100 (6): 388-398, 2008. (IF=14.069) 
 



Partecipazione a Meta-analisi, reviews etc.
 

Carrick S, Ghersi D, Wilcken N, Simes J.

Platinum containing regimens for metastatic breast cancer (Cochrane Review).

In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.  

Meta-Analysis Group in Cancer

Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.

British Journal of Cancer 84: 611-620, 2001 (IF=4.346) 
 

C.-H. Köhne, D. Cunningham, F. Di Costanzo, B. Glimelius, G. Blijham, E. Aranda, W. Scheithauer, P. Rougier, M. Palmer, J. Wils, B. Baron, F. Pignatti, P. Schöffski, S. Micheel and H. Hecker

Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

Annals of Oncology 13:308-317, 2002 (IF=5.647) 
 

Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Kohne CH.

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. 
Annals of Oncology 15: 1330-8, 2004 (IF=5.647)
 
 

Perrone F, Di Maio M, De Maio E, Maione P, Ottaiano A, Pensabene M, Di Lorenzo G, Vernaglia Lombardi A, Signoriello G, Gallo C.

Statistical design in phase II clinical trials and its application in breast cancer.

Lancet Oncol 4: 305-311, 2003 (IF=14.470) 
 

Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P; Meta-Analysis Group in Cancer.

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.

J Clin Oncol 22 (18): 3766-75, 2004. (IF=17.793) 
 

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trial.

Lancet 365: 1687-1717, 2005 (IF=30.758) 
 

Zia MI, Siu LL, Pond GR, Chen EX.

Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.

J Clin Oncol 23 (28): 6982-91, 2005. (IF=17.793) 
 

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y; Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. 
Lancet 366: 2087-106, 2005. (IF=30.758)

Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE.

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

J Clin Oncol. 24 (18): 2903-9, 2006. (IF=17.793) 
 

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

Lancet 371: 29-40, 2008. (IF=30.758) 
 

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast.

J Natl Cancer Inst Monogr 41: 162-177, 2010. (IF=14.069)


Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C.

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.

Cancer Immunol Immunother 59: 553-561, 2010 (IF=3.791) 
 

Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, and Perrone F. Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study.

J Clin Oncol 28 (10): 1645-51, 2010 (IF=17.793) 
 

Buti S, Lazzarelli S, Chiesa MD, Simonelli C, Lo Re G, Lheshi A, Simon S, Mattioli R, Caminiti C, Mazza G, Donini M, Passalacqua R; from the GOIRC (Italian Oncology Group for Clinical Research).

Dose-finding Trial of a Combined Regimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study.

J Immunother 33 (7): 735-41, 2010 (IF=3.203)



Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Lancet 378: 771-784, 2011 (IF=33.633)